Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Crystallisation of amorphous mannitol is retarded using boric acid.

Tomohiro Yoshinari1, Robert T Forbes, Peter York

  • 1Drug Delivery Group, The School of Pharmacy, University of Bradford, BD7 1DP, Bradford, UK.

International Journal of Pharmaceutics
|May 20, 2003
PubMed
Summary

Boric acid effectively inhibits amorphous mannitol crystallization, significantly slowing the rate by 7000 times. This additive enhances the stability of amorphous mannitol, crucial for pharmaceutical applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intermediate Term Results of a Novel Minimally Invasive Keratoprosthesis.

Ophthalmology science·2026
Same author

Discovery of KRAS(G12D) selective degrader ASP3082.

Communications chemistry·2025
Same author

Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population.

Hepatology research : the official journal of the Japan Society of Hepatology·2025
Same author

Evaluation of Drug-Polymer and Drug-Drug Interaction in Cellulosic Multi-Drug Delivery Matrices.

Methods and protocols·2025
Same author

"3D channel maze" to control drug release from multiple unit tablets.

Journal of controlled release : official journal of the Controlled Release Society·2024
Same author

Preliminary formulation of a fixed-dose paediatric combination of artesunate and amodiaquine hydrochloride.

MalariaWorld journal·2024

Area of Science:

  • Pharmaceutical Sciences
  • Materials Science
  • Physical Chemistry

Background:

  • Amorphous mannitol is prone to crystallization, impacting its stability and efficacy.
  • Controlling the crystallization of amorphous solids is vital for drug formulation and storage.

Purpose of the Study:

  • To investigate the use of boric acid as an additive to inhibit the crystallization of amorphous mannitol.
  • To characterize the properties of boric acid-mannitol amorphous solid mixtures.

Main Methods:

  • Differential Scanning Calorimetry (DSC) was used to analyze thermal properties and amorphous content.
  • The Gordon-Taylor equation was applied to assess the miscibility of mannitol and boric acid.
  • Crystallization kinetics were modeled using the Avrami-Eroféev equation.

Related Experiment Videos

Main Results:

  • Boric acid concentrations above 5% (w/w) enabled the preparation of fully amorphous mannitol-boric acid mixtures.
  • An increase in glass transition temperature (Tg) with rising boric acid content indicated homogeneous mixing.
  • Crystallization followed a random nucleation and three-dimensional growth mechanism (Avrami exponent n=1/3).
  • The activation energy for crystallization decreased with increasing boric acid content.
  • Mannitol crystallization rate at 30°C was reduced 7000-fold with 7.5% (w/w) boric acid.

Conclusions:

  • Boric acid is an effective crystallization inhibitor for amorphous mannitol.
  • The addition of boric acid significantly enhances the physical stability of amorphous mannitol.
  • The findings support the potential use of boric acid in stabilizing amorphous pharmaceutical formulations.